First Gene-Editing Therapies for Sickle Cell Disease, Casgevy and Lyfgenia, Approved by FDA

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 9, 2023.

By Physician’s Briefing Staff HealthDay Reporter

FRIDAY, Dec. 8, 2023 -- Two milestone gene therapies for sickle cell disease have been approved by the U.S. Food and Drug Administration.

Casgevy is the first medicine available in the United States to treat a genetic disease using the CRISPR gene-editing technique. The one-time treatment permanently changes DNA in a patient's blood cells, freeing them from the excruciating symptoms of sickle cell disease for life. The other approved therapy, Lyfgenia, uses a common virus to deliver genetic modifications to a patient's blood stem cells in their bone marrow.

In both therapies, stem cells are removed from a patient's blood for treatment. With Casgevy, CRISPR gene-editing technology knocks out a gene that triggers the development of defective, crescent-shaped blood cells. Meanwhile, medicine kills off flawed blood-producing cells in patients, who are then given back their own altered stem cells. The same thing happens with Lyfgenia, only a virus is used to deliver a genetic payload that causes the blood cells to start producing healthy hemoglobin. The genetically modified blood stem cells are then given back to the patient as a one-time, single-dose infusion.

Evidence supporting the approval of Casgevy was from a study of 44 patients treated with the gene-editing process. Out of 31 patients with sufficient follow-up time to be evaluated, 29 had complete freedom from the severe pain and organ damage that can occur during a sickle cell exacerbation. Furthermore, no patients experienced graft failure or graft rejection. Approval of Lyfgenia was supported by a 24-month study in which 32 patients received the therapy. Of those, 28 had no sickle cell events following their transplant.

Approval of Casgevy and Lyfgenia was granted to Vertex Pharmaceuticals and Bluebird Bio, respectively.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-12-11 08:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords